Lilly and BI Insulin Biosimilar Wins Positive CHMP Recommendation

Generic Line
A key European panel has recommended approval for Eli Lilly and Boehringer Ingelheim’s biosimilar of Sanofi’s blockbuster long-acting insulin drug Lantus, creating a potential threat to the French drugmaker’s multi-billion dollar product.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00